Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to the combined use of dietary modification (specifically, a cholesterol-lowering or "step 1" diet) and pravastatin, a pharmaceutical statin. Pravastatin is an HMG-CoA reductase inhibitor that lowers cholesterol by inhibiting the rate-limiting step in hepatic cholesterol biosynthesis, leading to increased clearance of LDL cholesterol from the bloodstream. The combination is used for managing hypercholesterolemia and reducing cardiovascular risk when dietary measures alone are insufficient. Clinical studies show that combining pravastatin with a low-fat diet results in greater reductions in serum total cholesterol than either intervention alone[1][4][5]. This approach is standard for patients with elevated blood lipids or at risk for cardiovascular disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diet + pravastatin.